

CITATION REPORT

List of articles citing

**Economic analysis as an aid to subsidisation decisions:
the development of Australian guidelines for pharmaceutical**

DOI: 10.2165/00019053-199201010-00010
Pharmacoeconomics, 1992, 1, 54-67.

Source: <https://exaly.com/paper-pdf/23205928/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
100	Doctors and the control of major releases of chemicals. <i>BMJ: British Medical Journal</i> , 1992 , 304, 1116-7		6
99	Principles of pharmacoeconomic analysis of drug therapy. <i>Pharmacoeconomics</i> , 1992 , 1, 20-31	4.4	111
98	The changing healthcare environment: socioeconomic evaluation of drug therapy. <i>Pharmacoeconomics</i> , 1992 , 1, 5-7	4.4	4
97	Clinical economics: a method for prospective health resource data collection. <i>Pharmacoeconomics</i> , 1992 , 1, 370-6	4.4	4
96	Cost-of-illness studies: a major headache?. <i>Pharmacoeconomics</i> , 1992 , 2, 1-4	4.4	197
95	The cost of migraine: more than just a headache?. <i>Pharmacoeconomics</i> , 1992 , 2, 5-7	4.4	17
94	Pharmaceutical formulation and healthcare expenditures. <i>Pharmacoeconomics</i> , 1992 , 2, 267-9	4.4	8
93	Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents. <i>Pharmacoeconomics</i> , 1992 , 2, 270-8	4.4	5
92	The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?. <i>Pharmacoeconomics</i> , 1992 , 2, 355-62	4.4	16
91	The Australian Guidelines for subsidisation of pharmaceuticals. <i>Pharmacoeconomics</i> , 1992 , 2, 422-6	4.4	9
90	Regulation of the pharmaceutical industry and now pharmacoeconomic research?. <i>Pharmacoeconomics</i> , 1992 , 2, 435-9	4.4	5
89	Overview of international pharmacy pricing. <i>Pharmacoeconomics</i> , 1992 , 2, 449-55	4.4	10
88	Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals. <i>Pharmacoeconomics</i> , 1993 , 3, 1-9	4.4	16
87	Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. <i>Pharmacoeconomics</i> , 1993 , 3, 354-61	4.4	107
86	Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. <i>Pharmacoeconomics</i> , 1993 , 3, 427-32	4.4	26
85	Economic evaluation of pharmaceuticals: a European perspective. <i>Pharmacoeconomics</i> , 1993 , 4, 173-86	4.4	45
84	Strategic use of pharmacoeconomic research in early drug development and global pricing. <i>Pharmacoeconomics</i> , 1993 , 4, 315-22	4.4	23

83	High technology drugs for cancer: the decision process for adding to a formulary. <i>Pharmacoeconomics</i> , 1993 , 4, 405-13	4.4	3
82	Integration of economic appraisal and health care policy in a health insurance system; the Dutch case. <i>Social Science and Medicine</i> , 1994 , 38, 1609-14	5.1	10
81	Standardizing economic appraisal of health technology in the European Community. <i>Social Science and Medicine</i> , 1994 , 38, 1675-8	5.1	13
80	Gesundheitsökonomie als Fachgebiet. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 1994 , 2, 131-148	1.4	1
79	Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma. <i>Australasian Journal of Dermatology</i> , 1994 , 35, 71-5	1.3	10
78	Drug utilisation studies as tools in health economics. <i>Pharmacoeconomics</i> , 1994 , 5, 299-312	4.4	16
77	Is there a need for an independent centre for pharmacoeconomics in the UK?. <i>Pharmacoeconomics</i> , 1994 , 5, 93-100	4.4	10
76	Costing and funding of healthcare in Australia: pharmaceuticals in context. <i>Pharmacoeconomics</i> , 1994 , 5, 180-7	4.4	
75	Statistical versus quantitative significance in the socioeconomic evaluation of medicines. <i>Pharmacoeconomics</i> , 1994 , 5, 389-98	4.4	49
74	Australian pharmaceutical pricing guidelines: preliminary practical experience. <i>Pharmacoeconomics</i> , 1994 , 5, 465-71	4.4	1
73	Applying the Australian guidelines for the reimbursement of pharmaceuticals. <i>Pharmacoeconomics</i> , 1994 , 6, 196-201	4.4	12
72	Using cost-effectiveness analysis for formulary decision making: from theory into practice. <i>Pharmacoeconomics</i> , 1994 , 6, 281-8	4.4	3
71	Pharmacists: grasp the opportunities presented by pharmacoeconomics. <i>Drugs and Therapy Perspectives</i> , 1994 , 4, 14-16	1.5	
70	Some factors to consider when using the results of economic evaluation studies at the population level. <i>International Journal of Technology Assessment in Health Care</i> , 1994 , 10, 467-78	1.8	15
69	From principle to public policy: using cost-effectiveness analysis. <i>Health Affairs</i> , 1994 , 13, 206-14	0	15
68	The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. <i>International Journal of Technology Assessment in Health Care</i> , 1995 , 11, 79-92 ¹⁸		57
67	Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?. <i>International Journal of Technology Assessment in Health Care</i> , 1995 , 11, 750-61	1.8	12
66	The clinical-economic trial: promise, problems, and challenges. <i>Contemporary Clinical Trials</i> , 1995 , 16, 377-94		48

65	Methods of cost-effectiveness analysis: areas of consensus and debate. <i>Clinical Therapeutics</i> , 1995 , 17, 109-25	3.5	38
64	Use of anesthesia selection in controlling surgery costs in an HMO hospital. <i>Clinical Therapeutics</i> , 1995 , 17, 561-71; discussion 516	3.5	18
63	A note on the depreciation of the societal perspective in economic evaluation of health care. <i>Health Policy</i> , 1995 , 33, 59-66	3.2	26
62	Economic evaluation of health care and policymaking. <i>Health Policy</i> , 1995 , 33, 179-90	3.2	13
61	The role of pharmacoeconomics in health policy and management in Norway. <i>Pharmacoeconomics</i> , 1995 , 7, 475-83	4.4	2
60	Economic evaluation of drugs and its potential uses in policy making. <i>Pharmacoeconomics</i> , 1995 , 8, 190-8	4.4	17
59	Cost-effectiveness guidelines. The experience of Australian manufacturers. <i>Pharmacoeconomics</i> , 1995 , 8, 369-73	4.4	5
58	Incorporating quality of life changes into economic evaluations of health care: an overview. <i>Health Policy</i> , 1996 , 36, 155-66	3.2	11
57	Costs, innovation and efficiency in anti-infective therapy. <i>Pharmacoeconomics</i> , 1996 , 9 Suppl 1, 31-9	4.4	2
56	Economic evaluation in healthcare. A brief history and future directions. <i>Pharmacoeconomics</i> , 1996 , 10, 114-22	4.4	21
55	Pharmacoeconomic studies. Pitfalls and problems. <i>International Journal of Technology Assessment in Health Care</i> , 1996 , 12, 22-30	1.8	4
54	Paper two: Allocation of scarce resources: The need for critical analysis. <i>Health Care Analysis</i> , 1996 , 4, 28-34	2.3	1
53	Qualitative research in health care: II. A structured review and evaluation of studies. <i>Journal of Evaluation in Clinical Practice</i> , 1996 , 2, 171-9	2.5	74
52	Cost Containment Strategies in the United States: Role of Cost-Effectiveness Research. <i>Drug Information Journal</i> , 1996 , 30, 609-619		1
51	Are methods for estimating QALYs in cost-effectiveness analyses improving?. <i>Medical Decision Making</i> , 1997 , 17, 402-8	2.5	61
50	Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones. <i>Pharmacoeconomics</i> , 1997 , 11, 64-74	4.4	17
49	Why training is the key to successful guideline implementation. <i>Pharmacoeconomics</i> , 1997 , 12, 297-302	4.4	4
48	Are quality of life, patient preferences, and costs realistic outcomes for clinical trials?. <i>Supportive Care in Cancer</i> , 1997 , 5, 112-7	3.9	5

47	Methods for conducting and reporting cost-effectiveness analysis in nursing. <i>Journal of Nursing Scholarship</i> , 1998 , 30, 229-34		6
46	The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?. <i>Pharmacoeconomics</i> , 1998 , 13, 389-96	4.4	23
45	A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?. <i>Pharmacoeconomics</i> , 1998 , 14, 1-9	4.4	33
44	Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece. <i>Pharmacoeconomics</i> , 1998 , 14, 575-88	4.4	6
43	Ethics and evidence based medicine. <i>BMJ: British Medical Journal</i> , 1998 , 316, 1151-3		93
42	Quality-of-life assessment in health care research and practice. <i>Evaluation and the Health Professions</i> , 1998 , 21, 141-56	2.5	13
41	Techniques for health economics analysis in oncology: Part 1. <i>Critical Reviews in Oncology/Hematology</i> , 1999 , 30, 1-11	7	7
40	Cost-effectiveness analysis in the treatment of hypertension: a medical view. <i>Clinical and Experimental Hypertension</i> , 1999 , 21, 999-1008	2.2	6
39	Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. <i>Clinical Therapeutics</i> , 1999 , 21, 255-67	3.5	33
38	Development of WHO guidelines on generalized cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 2000 , 9, 235-51	2.4	334
37	Cost-effectiveness of neonatal surgery: a review. <i>Journal of Pediatric Surgery</i> , 2000 , 35, 588-92	2.6	11
36	Medical economic considerations of supportive cancer care. <i>International Journal of Antimicrobial Agents</i> , 2000 , 16, 181-4	14.3	1
35	Model-Based Drug Evaluation in Chronic Disease: Promise, Pitfalls, and Positioning. <i>Drug Information Journal</i> , 2001 , 35, 131-139		3
34	Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. <i>Pharmacoeconomics</i> , 2002 , 20, 775-84	4.4	34
33	Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?. <i>Medical Journal of Australia</i> , 2002 , 177, 428-34	4	18
32	The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. <i>Value in Health</i> , 2003 , 6, 505-21	3.3	26
31	Issues for countries considering introducing the "fourth hurdle": the case of Hungary. <i>International Journal of Technology Assessment in Health Care</i> , 2004 , 20, 337-41	1.8	20
30	Recent developments in targeting access to high cost medicines in Australia. <i>Australia and New Zealand Health Policy</i> , 2005 , 2, 28		4

29	[Economic evaluation studies in health]. <i>Medicina Clínica</i> , 2005 , 125 Suppl 1, 61-71	1	3
28	Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. <i>Globalization and Health</i> , 2005 , 1, 15	10	16
27	Information created to evade reality (ICER): things we should not look to for answers. <i>Pharmacoeconomics</i> , 2006 , 24, 1121-31	4.4	67
26	Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts. <i>Pharmacoeconomics</i> , 2006 , 24, 345-54	4.4	14
25	Considerations in developing model-based economic evaluations of glaucoma treatment. <i>Journal of Glaucoma</i> , 2006 , 15, 541-7	2.1	2
24	The new drugs advent: clinical or economic outcomes?. <i>Annals of Oncology</i> , 2006 , 17 Suppl 2, ii88-90	10.3	1
23	The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. <i>Australia and New Zealand Health Policy</i> , 2007 , 4, 2		18
22	Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden. <i>Health Economics, Policy and Law</i> , 2007 , 2, 153-71	2.3	20
21	Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia. <i>International Journal of Rheumatic Diseases</i> , 2008 , 11, 11-14	2.3	2
20	Meeting the information needs of a national drug payer: aspirations of the guidelines from Australia. <i>Drug Development Research</i> , 2010 , 71, 463-469	5.1	4
19	Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. <i>Medical Decision Making</i> , 2012 , 32, 678-89	2.5	158
18	Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. <i>Value in Health</i> , 2012 , 15, 804-11	3.3	129
17	Standardization and regulatory guidelines may inhibit science and reduce the usefulness of analyses based on the application of preference-based measures for policy decisions. <i>Medical Decision Making</i> , 2013 , 33, 316-9	2.5	11
16	Health state descriptions to elicit stroke values: do they reflect patient experience of stroke?. <i>BMC Health Services Research</i> , 2014 , 14, 573	2.9	7
15	New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations. <i>Health Policy</i> , 2017 , 121, 836-841	3.2	35
14	Commentary. In Praise of Studies That Use More Than One Generic Preference-Based Measure. <i>International Journal of Technology Assessment in Health Care</i> , 2019 , 35, 257-262	1.8	6
13	Interpreting Pharmacoeconomic Findings. 2019 , 277-287		4
12	Assessment of External Price Referencing and Alternative Policies. 2019 , 369-419		

11	Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses. <i>Pharmacoeconomics</i> , 2020 , 38, 809-818	4.4	3
10	Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. <i>Medical Care</i> , 1996 , 34, 702-22	3.1	709
9	Pharmakoökonomie bei Infektionskrankheiten. 2004 , 1425-1438		
8	Economics and the fundamental principles of the NHS. <i>BMJ: British Medical Journal</i> , 1992 , 304, 1117		
7	Quality of Life Assessments in Clinical Trials of Angina Pectoris. <i>Developments in Cardiovascular Medicine</i> , 1994 , 31-40		1
6	Economic Evaluation and Policy Making. <i>Developments in Health Economics and Public Policy</i> , 1996 , 221-236		
5	Medizinische Ökonomie Eine neue Herausforderung für die Ärzteschaft. 1998 , 151-178		
4	Evolution of the AMCP Format for Formulary Submissions. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 696-700	1.9	
3	Drug policy down under: Australia's pharmaceutical benefits scheme. <i>Health Care Financing Review</i> , 2004 , 25, 55-67		27
2	Health technology assessment for gene therapies in haemophilia.. <i>Haemophilia</i> , 2022 ,	3.3	2
1	Evidence-based Economic Evaluation. 2003 , 64-70		0